Effectively targetting the renin-angiotensin-aldosterone system in cardiovascular and renal disease: Rationale for using angiotensin II receptor blockers in combination with angiotensin-converting enzyme inhibitors

JRAAS - Journal of the Renin-Angiotensin-Aldosterone System

Volumn 1, Issue 3, 2000, Pages 217-233

  Weinberg, Marc S ^a   Weinberg, Adam J ^a   Zappe, Dion H ^b  

^a BOSTON UNIVERSITY   (United States)

^b ASTRAZENECA   (United Kingdom)

Author keywords

Angiotensin II receptor blockers; Angiotensin converting enzyme Inhibitors; AT1 receptors; Chymase; Diabetic renal disease; End organ protection; Heart failure; Hypertension; Kinins; Renin

Indexed keywords

ALDOSTERONE; ANGIOTENSIN RECEPTOR; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ANIMAL; CARDIOVASCULAR DISEASE; DRUG ANTAGONISM; EDITORIAL; HUMAN; KIDNEY DISEASE; PATHOPHYSIOLOGY; PHYSIOLOGY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM;

ALDOSTERONE; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; CARDIOVASCULAR DISEASES; HUMANS; KIDNEY DISEASES; RECEPTORS, ANGIOTENSIN; RENIN-ANGIOTENSIN SYSTEM;

EID: 0034286103     PISSN: 14703203     EISSN: None     Source Type: Journal    
DOI: 10.3317/jraas.2000.034     Document Type: Review

References (199)

1. Pitt B. ACE inhibition in heart failure: prospects and limitations. Cardiovasc Drugs Ther 1997; 11:285-90.
2. Remuzzi G. Editorial. Renoprotective effect of ACE-inhibitors: dissecting the molecular clues and expanding the blood pressure goal. Am J Kidney Dis 1999; 34(5):951-3.
3. Biollaz J, Brunner HR, Gavras I, Waeber B, Gravas H. Antihypertensive therapy with MK 421: angiotensin II-renin relationships to evaluate efficacy of converting enzyme blockade. J Cardiovasc Pharmacol 1982; 4(6): 966-72.
4. Mooser V, Nussberger J, Juillerat L et al. Reactive hyperreninemia is a major determinant of plasma angiotensin II during ACE inhibition. J Cardiovasc Pharmacol 1990; 15(2): 276-82.
5. Nussberger J, Juillerat L, Perret F, Waeber B, Bellet M, Brunner J, Menard J. Need for plasma angiotensin measurements to investigate converting-enzyme inhibition in humans. Am Heart J 1989; 117(3): 717-22.
6. Dzau VJ. Short- and long-term determinants of cardiovascular function and therapy: contributions of circulating and tissue renin-angiotensin systems. J Cardiovasc Pharmacol 1989; 14(Suppl 4):S1-5.
7. Johnston CI. Renin-angiotensin system: a dual tissue and hormonal system for cardiovascular control. J Hypertens 1992; 10(Suppl 7):S13-26.
8. Dzau VJ, Re R. Tissue angiotensin system in cardiovascular medicine: a paradigm shift? Circulation 1994; 89: 493-98.
9. Rakugi H. Wang DS, Dzau VJ, Pratt RE. Potential importance of tissue angiotensin-converting enzyme inhibition in preventing neointima formation. Circulation 1994; 90(1): 449-55.
10. Peters H, Ritz E. Dosing angiotensin II blockers - beyond blood pressure. Nephrol Dial Transplant 1999; 14: 2568-70.
11. Ruilope LM. Is it wise to combine an ACE inhibitor and an angiotensin receptor antagonist? Nephrol Dial Transplant 1999; 14(12): 2855-6.
12. Azizi M, Menard J. Combined blockade of the reninangiotensin system. Arch Mal Coeur Vaiss 1999; 92(6): 735-9.
13. Webb RL, Navarrete AE, Davis S, de-Gasparo M. Synergistic effects of combined converting enzyme inhibition and angiotensin II antagonism on blood pressure in conscious telemetered spontaneously hypertensive rats. J Hypertens 1998; 16(6): 843-52.
14. Menard J, Campbell DJ, Azizi M, Gonzales ME Synergistic effects ACE inhibition and Ang II antagonism on blood pressure cardiac weight and renin in spontaneously hypertensive rats. Circulation 1997; 96(9): 3072-8.
15. Azizi M, Chatellier G, Guyene TT, Murieta-Geoffroy D, Menard J. Additive effects of combined angiotensin on blood pressure and renin release in sodium deplete normotensives. Circulation 1995; 92(4): 825-34.
16. Baruch L, Anand I, Cohen IS, Ziesche S, Judd D, Cohn JN. Augmented short- and long-term hemodynamic and hormonal effects of an angiotensin receptor blocker added to angiotensin converting enzyme inhibitor therapy in patients with heart failure. Circulation 1999; 99(20): 2658-64.
17. Hebert LA, Falkenhain ME, Nahman NS, Cosio FG, Dorisio TM. Combination ACE inhibitor and angiotensin II receptor antagonist therapy in diabetic nephropathy. Am J Nephrol 1999; 19(1): 1-6.
18. Juillerat L, Nussberger J, Menard J et al. Determinants of angiotensin II generation during converting enzyme inhibition. Hypertension 1990; 16(5): 564-72.
19. MacFadyen RJ, Lee AF, Morton JJ, Pringle SD, Struthers AD. How often are angiotensin II and aldosterone concentrations raised during chronic ACE inhibitor treatment in cardiac failure? Heart 1999; 82: 57-61.
20. Roig E, Perez-Villa F, Morales M, Jimenez W, Orus J, Heras M, Sanz G. Clinical implications of increased plasma angiotensin II despiteACE inhibitor therapy in patients with congestive heart failure. Eur Heart J 2000; 21(1): 53-7.
21. Van den Meiracker AH, Man-in-T-Veld AJ et al. The pharmacokinetic and pharmacodynamic interactions of ramipril with propranolol. Eur J Clin Pharmacol 1993; 45(3): 255-60.
22. Nussberger J, Brunner DB, Waeber B, Brunner HR. Plasma angiotensins under sustained converting enzyme inhibition with enalapril in normal humans. J Hypertens 1985; 3(Suppl 3):S269-70.
23. Nussberger J, Waeber G, Waeber B, Bidiville J, and Brunner HR. Plasma angiotensin-(1-8) octapeptide measurement to assess acute angiotensin-converting enzyme inhibition with captopril administered parenterally to normal subjects. J Cardiovasc Pharmacol 1988; 11(6): 716-21.
24. Campbell DJ. Endogenous angiotensin II levels and the mechanism of action of angiotensin-converting enzyme inhibitors and angiotensin receptor type 1 antagonists. Clin Exp Pharmacol Physiol 1996;(Suppl 3):S125-31.
25. Pinto YM, van Geel PP, Alkfaji H, van Veldhuisen DJ, van Gilst WH. Dosing of ACE inhibitors in left ventricular dysfunction: does current clinical dosing provide optimal benefit? J Cardiovasc Pharmacol 1999; 34(Suppl 1): S13-7.
26. Sander GE, McKinnie JJ, Greenberg SS, Giles TD. Angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists in the treatment of heart failure caused by left ventricular systolic dysfunction. Prog Cardiovasc Dis 1999; 41(4): 265-300.
27. Arzilli F, Magagna A, Giovannetti R, Nuccorini A, Salvetti A. Acute dose-response curve of enalapril in renovascular hypertensives. Am J Hypertens 1988; 1(3): S75-8.
28. Jorde UP, Ennezat PV, Lisker J et al. Maximally recommended doses of angiotensin-converting enzyme (ACE) inhibitors do not completely prevent ACE-mediated formation of angiotensin II in chronic heart failure. Circulation 2000; 101(8): 844-6.
29. Cirillo VJ, Gomez HJ, Salonen J et al. Lisinopril: dose-peak effect relationship in essential hypertension. Br J Clin Pharmacol 1988; 25(5): 533-8.
30. Schnaper HW. Dose-response relationship of ramipril in patients with mild-to-moderate hypertension. J Cardiovasc Pharmacol 1991; 18(Suppl 2): S128-30.
31. Frishman WH: The safety and efficacy of quinapril in the treatment of mild to moderate essential hypertension. Clin Cardiol 1990; 6( Suppl 7):VII19-VII25.
32. Brunner-La Rocca HP, Weilenmann D, Kiowski W, Maly FE, Candinas R, Follath F. Within-patient comparison of effects of different dosages of enalapril on functional capacity and neurohormone levels in patients with chronic heart failure. Am Heart J 1999; 138(4): 654-62.
33. Gansevoort RT, de-Zeeuw D, dejong PE. Is the antiproteinuric effect of ACE inhibition mediated by interference in the renin-angiotensin system? Kidney Int 1994; 45(3): 861-7.
34. Packer M, Poole-Wilson PA, Armstrong PW, Cleland JGF, Horowitz JD, Massie BM, Ryden L, Thygesen K, Uretsky BF for the ATLAS Study Group. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor lisinopril on morbidity and mortality in chronic heart failure. Circulation 1999; 100: 2312-8.
35. Palla R, Panichi V, Finato V et al. Effect of increasing doses of lisinopril on proteinuria of normotensive patients with IgA nephropathy and normal renal function. Int J Clin Pharmacol Res 1994; 14(1): 35-43.
36. Blaine EH. Characteristics of the blood pressure lowering action of renin inhibition and comparison with angiotensin converting enzyme inhibition. J Hypertens 1989; 7(Suppl 2): S47-9.
37. Inglessis N, Nussberger J, Hagmann M et al. Comparison of the angiotensin II antagonist UP269-6 with the angiotensin converting enzyme inhibitor enalapril in normotensive volunteers challenged with angiotensin I. J Cardiovasc Pharmacol 1995; 25(6): 986-93.
38. Nussberger J, Waeber B, Brunner HR. Plasma angiotensin II and the antihypertensive action of angiotensin-converting enzyme inhibition. Am J Hypertens 1989; 2(4): 286-93.
39. Salgado MC, Caldo H, Pinheiro MA. Discrepancy between plasma angiotensin converting enzyme activity and in vivo extent of angiotensin I conversion in hypertensive rats. Braz J Med Biol Res 1991; 24(3): 311-8.
40. Asmar RG, Benetos A, Darne BM, Pauly NC, Safar ME. Converting enzyme inhibition: dissociation between antihypertensive and arterial effects. J Hum Hypertens 1992; 6(5):381-385.
41. Borland JAA, Chester AH, Morrison KA, Yacoub MH. Alternative pathways of angiotensin II production in the human saphenous vein. BrJ Pharmacol 1998; 125(3): 423-8.
42. Hollenberg NK, Fisher NDL, Price DA. Pathways for angiotensin II generation in intact human tissue. Evidence from comparative pharmacological interruption of the renin system. Hypertension 1998; 32: 387-92.
43. Okunishi H, Oka Y, Shiota N, Kawamoto T, Song K, Miyazaki M. Marked species-difference in the vascular angiotensin II-forming pathways: humans versus rodents. Jpn J Pharmacol 1993; 62(2): 207-10.
44. Hollenberg NK. Implications of species differences for clinical investigation. Hypertension 2000; 35: 150-4.
45. Wolny A, Clozel JP, Rein J et al. Functional and biochemical analysis of angiotensin II-forming pathways in the human heart. Circulation Res 1997; 80(2): 219-27.
46. Liao Y, Husain A. The chymase-angiotensin system in humans: biochemistry molecular biology and potential role in cardiovascular diseases. Can J Cardiol 1995; 11(Suppl F): 13F-9F.
47. Urata H, Healy B, Stewart RW, Bumpus FM, Husain A. Angiotensin-II forming pathways in normal and failing hearts. Circ Res 1990; 66: 883-90.
48. Murakami M, Matsuda H, Kubota E, Wakino S, Honda M, Hayashi K, Saruta T. Role of angiotensin II generated by angiotensin converting enzyme-independent pathways in canine kidney. Kidney Int 1997; 52(Suppl 63): S132-5.
49. Weir MR, Dzau VJ. The renin-angiotensin-aldosterone system: a specific target for hypertension management. Am J Hypertens 1999; 12(12; Pt. 3): S205-13.
50. Rousseau MF, Konstam MA, Benedict et al. Progression of left ventricular dysfunction secondary to coronary artery disease sustained neurohormonal activation and effects of ibopamine therapy during long-term therapy with angiotensin-converting enzyme inhibitor. Am J Cardiol 1994; 73: 488-93.
51. Califf RM, Cohn JN. Cardiac protection: evolving role of angiotensin receptor blockers. Am Heart J 2000; 139(1 Pt 2): 15-22.
52. Ihara M, Urata H, Kinoshita A et al. Increased chymase-dependent angiotensin II formation in human atherosclerotic aorta. Hypertension 1999; 33(6): 1399-1405.
53. MacFadyen RJ, Lees KR, Reid JL. Tissue and plasma angiotensin converting enzyme and the response to ACE inhibitor drugs. Br J Clin Pharmacol 1991; 31(1): 1-13.
54. Ingert C, Grima M, Michel B, Barthelmebs M, Imbs JL. Renal tissue angiotensins during converting enzyme inhibition of angiotensin I in spontaneously hypertensive rat. Archiv Malad Coeur Vaisseaux 1997; 90(8): 1135-41.
55. Anderson S. Role of local and systemic angiotensin in diabetic renal disease. Kidney Int 1997; 52(Suppl 63):S107-10.
56. Jover B, Mimran A. Angiotensin II receptor antagonists versus angiotensin converting enzyme inhibitors: effects on renal function. J Hypertens 1994; 12(Suppl 9):S3-9.
57. Braam B, Koomans HA. Renal responses to antagonism of the renin-angiotensin system. Curr Opin Nephrol Hypertens 1996; 5: 89-96.
58. Peters H, Border WA, Noble NA.Targeting TGF-beta overexpression in renal disease: Maximizing the antifibrotic action of angiotensin II blockade. Kidney Int 1998; 54(5): 1570-80.
59. Nakamura T, Obata J, Kimura H, Ohno S, Yoshida Y, Kawachi H, Shimizu F. Blocking angiotensin II ameliorates proteinuria and glomerular lesions in progressive mesangioproliferative glomerulonephritis. Kidney Int 1999; 55(3): 877-89.
60. Tazawa S, NakaneT, Chiba S. Angiotensin II type 1 receptor blockade prevents up-regulation of angiotensin II type 1A receptors in rat injured artery. J Pharmacol Exp Therap 1999; 288(2): 898-904.
61. Sachinidis A, Elhaschimi K, Ko Y, Seul C, Dusing R, Vetter H. CV-11974, the active metabolite of TCV-116 (candesartan) inhibits the synergistic or additive effect of different growth-factors on angiotensin-II-induced proliferation of vascular smooth-muscle cells. Biochem Pharmacol 1996; 52(1): 123-6.
62. Zandi-Nejad K, Kusaka M, Taal MW, Ziai F, Kato S, Brenner DM, Mackenzie HS. Effects of candesartan and enalapril on cytokine expression in remnant kidney of munich-wistar (mw) rats 3 months after 5/6 nephrectomy (NPX). J Am Soc Nephrol 1998; 9: 626A.
63. CsikosT, Chung O, Unger T. Receptors and their classification: focus on angiotensin II and the AT2 receptor. J Hum Hypertens 1998; 12(5): 311-8.
64. Chung O, Kuhl H, Stoll M, Unger T. Physiological and pharmacological implications of versus AT2 receptors. Kidney Int 1998; 54(Suppl67):S95-9.
65. Maruyama K, Horiuchi M, Dzau VJ, Takahashi H, Iwasaka T, Inada M, Matsubara H. Cardiac-specific overexpression of angiotensin II AT2 receptor causes attenuated response to AT1 receptor-mediated pressor and chronotropic effects. J Clin Invest 1998; 101(3): 527-35.
66. Tsutsumi Y, Matsubara H, Masaki H et al. Angiotensin II type 2 receptor overexpression activates the vascular kinin system and causes vasodilation. J Clin Incest 1999; 104(7): 925-35.
67. Siragy HM, Carey RM. The subtype 2 (AT2) angiotensin receptor mediates renal production of nitric oxide in conscious rats. J Clin Invest 1997; 100(2): 264-9.
68. Jalowy A, Schulz R, Dorge H, Behrends M, Heusch G. Infarct size reduction by AT1-receptor blockade through a signal cascade of AT2-receptor activation bradykinin and prostaglandins in pigs. J Am Coll Cardiol 1998; 32(6): 1787-96.
69. Cohn JN, Tognoni G, Glazer RD, Spormann D, Hester A. Rationale and design of the Valsartan Heart Failure Trial: a large multinational trial to assess the effects of valsartan an angiotensin-receptor blocker on morbidity and mortality in chronic congestive heart failure. J Card Fail 1999; 5(2): 155-60.
70. Mazzolai L, Maillard M, Rossat J, Nussberger J, Brunner HR, Burnier M. Angiotensin II receptor blockade in normotensive subjects: a direct comparison of three ATI receptor antagonists. Hypertension 1999; 33(3): 850-5.
71. Brunner-La Rocca HP, Vaddadi G, Esler MD. Recent insight into therapy of congestive heart failure: focus on ACE Inhibition and Angiotensin-II antagonism. J Am Coll Cardiol 1999; 33: 1163-73.
72. Messerli F. Editorial. ...And losartan was no better than placebo. J Hum Hypertens 1999; 13: 649-50.
73. Vanderheyden PML, Fierens FLP, DeBacker JP, Fraeyman N, Vauquelin G. Distinction between surmountable and insurmountable selective AT receptor antagonists by use of CHO-K1 cells expressing human angiotensin II AT receptors. Br J Pharmacol 1999; 126: 1057-65.
74. Brown NJ, Agirbasli M, Vaughan DE. Comparative effect of angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor antagonism on plasma fibrinolytic balance in humans. Hypertension 1999; 34(2): 285-90.
75. Kerins DM, Hao Q, Vaughan DE. Angiotensin induction of PAI-1 expression in endothelial cells is mediated by the hexapeptide angiotensin IV. J Clin Invest 1995; 96(5): 2515-20.
76. Ridker PM, Gaboury CL, Conlin PR, Seely EW, Williams GH, Vaughan DE. Stimulation of plasminogen activator inhibitor in vivo by infusion of angiotensin II. Evidence of a potential interaction between the renin-angiotensin system and fibrinolytic function. Circulation 1993; 87(6): 1969-73.
77. Goodfield NER, Newby DE, Ludlam CA, Flapan AD. Effects of acute angiotensin II type 1 receptor antagonism and angiotensin converting enzyme inhibition on plasma fibrinolytic parameters in patients with heart failure. Circulation 1999; 99: 2983-5.
78. Nishimura H, Tsuji H, Masuda H et al. Angiotensin II increases plasminogen activator inhibitor-1 and tissue factor mRNA expression without changing that of tissue type plasminogen activator or tissue factor pathway inhibitor in cultured rat aortic endothelial cells. Thromb Haemost 1997; 77(6): 1189-95.
79. Shihab FS, Bennett WM, Tanner AM, Andoh TF. Angiotensin II blockade decreases TGF-beta1 and matrix proteins in cyclosporine nephropathy. Kidney Int 1997; 52(3): 660-73.
80. Timmermans PB. Angiotensin II receptor antagonists: an emerging new class of cardiovascular therapeutics. Hypertens Res 1999; 22: 147-53.
81. Dzau VJ. Tissue renin-angiotensin system in myocardial hypertrophy and failure. Arch Intern Med 1993; 153(8): 937-12.
82. Unger T, Ganten D, Lang RE, Scholkens BA. Is tissue converting enzyme inhibition a determinant of the antihypertensive efficacy of converting enzyme inhibitors? Studies with the two different compounds Hoe498 and MK421 in spontaneously hypertensive rats. J Cardiovasc Pharmacol 1984; 6: 872-80.
83. Cashin-Hemphill L, Holmvang G, Chan RC, Pitt B, Dinsmore RE, Lees RS. Angiotensin-converting enzyme inhibition as antiatherosclerotic therapy: no answer yet. QUIET Investigators. QUinapril Ischemic Event Trial. Am J Cardiol 1999; 83(1): 43-7.
84. Faxon DP. Effect of high dose angiotensin-converting enzyme inhibition on restenosis: final results of the MERCATOR study, a multicenter, double-blind, placebo-controlled trial of cilazipril. J Am Coll Cardiol 1995; 25: 362-9.
85. MERCATOR Study Group. Results of the Multicenter European Research trial with Cilazapril after Angioplasty to prevent Transluminal coronary Obstruction and Restenosis (MERCATOR) study: a multicenter randomized double-blind placebo-controlled trial. Circulation 1992; 86: 100-10.
86. Linz W, Wiemer G, Gohlke P, Unger T, Scholkens BA. Contribution of kinins to the cardiovascular actions of angiotensin-converting enzyme inhibitors. Pharmacol Rev 1995; 47(1): 25-49.
87. Carretero OA, Scicli AG. The kallikrein-kinin system as a regulator of cardiovascular and renal function in Laragh JH Brenner BM (eds): Hypertension: Pathophysiology Diagnosis and Management (2nd ed). New York, Raven Press 1995; 983-99.
88. Liu YH, Yang XP, Sharov VG, Nass O, Sabbah HN, Peterson E, Carretero OA. Effects of angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists in rats with heart failure. J Clin Invest 1997; 99: 1926-35.
89. Gainer JV, Morrow JD, Loveland A, King DJ, Brown NJ. Effect of bradykinin-receptor blockade on the response to angiotensin-converting-enzyme inhibitor in normotensive and hypertensive subjects. New Engl J Med 1998; 339(18): 1285-92.
90. Hall JE. Control of blood pressure by the reninangiotensin-aldosterone system. Clin Cardiol 1991; 14(Suppl IV):IV6-IV21.
91. Weinberg MS, Belknap S, Trebbin W, Solomon RJ. Effects of changing salt and water balance on renal kallikrein kininogen and kinin. Kidney Int 1987; 31: 836-41.
92. Pitt B, Chang P, Grossman W, Dunlay M, Timmermans PB. Rationale background and design of the randomized angiotensin receptor antagonist-angiotensin-converting enzyme inhibitor study (RAAS). Am J Cardiol 1996; 78(10): 1129-31.
93. Ferrario CM, Chappell MC, Dean RH, Iyer SN. Novel angiotensin peptides regulate blood pressure endothelial function and natriuresis. J Am Soc Nephrol 1998; 9(9): 1716-22.
94. Iyer SN, Chappell MC, Averill DB, Diz DI, Ferrario CM. Vasodepressor actions of angiotensin-(1-7) unmasked during combined treatment with lisinopril and losartan. Hypertension 1998; 31(2): 699-705.
95. Ogihara T, Arakawa K. Clinical efficacy and tolerability of candesartan cilexetil. J Hum Hypertens 1999; 13(Suppl 1): S27-31.
96. Black HR, Graff A, Shute D, Stoltz R, Ruff D, Levine J, Shi Y, Mallows S. Valsartan a new angiotensin II antagonist for the treatment of essential hypertension; efficacy tolerability and safety compared to an angiotensin-converting enzyme inhibitor lisinopril. J Hum Hypertens 1997; 11(8): 483-9.
97. Bremner AD, Baur M, Oddou-Stock P, Bodin F. Valsartan: long-term efficacy and tolerability compared to lisinopril in elderly patients with essential hypertension. Clin Exp Hypertens 1997; 19(8): 1263-85.
98. Franke H. Antihypertensive effects of candesartan cilexetil enalapril and placebo. J Hum Hypertens 1997; 11(Suppl 2): S61-2.
99. Holwerda NJ, Fogari R, Angeli P, Porcellati C, Hereng C, Oddou-Stock P, Heath R, Bodin F. Valsartan a new angiotensin II antagonist for the treatment of essential hypertension: efficacy and safety compared with placebo and enalapril. J Hypertens 1996; 14: 1147-51.
100. LaRochelle P, Flack JM, Marbury TC, Sareli P, Krieger EM, Reeves RA. Effects and tolerability of irbesartan versus enalapril in patients with severe hypertension. Am J Cardiol 1997; 80(12): 1613-5.
101. Mimran A, Ruilope L, Kerwin L, Nys M, Owens D, Kassler-Taub K, Osbakken M. A randomised double-blind comparison of the angiotensin II receptor antagonist irbesartan with the full-dose range of enalapril for the treatment of mild-to-moderate hypertension. J Hum Hypertens 1998; 12(3): 203-8.
102. Neutel JM, Frishman WH, Oparil S, Papademitrioti V, Guthrie G. Comparison of telmisartan with lisinopril in patients with mild-to-moderate hypertension. Am J Ther 1999; 6(3): 161-6.
103. Pechere-Bertschi A, Nussberger J, Decosterd L et al. Renal responses to the angiotensin II receptor subtype 1 antagonist irbesartan versus enalapril in hypertensive patients. J Hypertens 1998; 16: 385-93.
104. Smith DHG, Neutel JM, Morgenstern P. Once-daily telmisartan compared with enalapril in the treatment of hypertension. Adv Ther 1998; 15(4): 229-40.
105. Townsend R, Haggert B, Liss C, Edelman JM. Efficacy and tolerability of losartan versus enalapril alone or in combination with hydrochlorothiazide in patients with essential hypertension. Clin Therap 1995; 17(5): 911-23.
106. Zanchetti A, Omboni S, Di-Biagio C. Candesartan cilexetil and enalapril are of equivalent efficacy in patients with mild to moderate hypertension. J Hum Hypertens 1997; 11(Suppl 2): S57-9.
107. Gradman A, Arcuri KE, Goldberg AI, Ikeda LS, Nelson EB, Snavely DB, Sweet CS. A randomized placebo-controlled double-blind parallel study of various doses of losartan potassium compared with enalapril maleate in patients with essential hypertension. Hypertension 1995; 25:1345-50.
108. Tikkanen I, Omvik P, Jensen HA. Comparison of the angiotensin II antagonist losartan with the angiotensin converting enzyme inhibitor enalapril in patients with essential hypertension. J Hypertens 1995; 13(11): 1343-51.
109. Ruff D, Gazdick LP, Berman R, Goldberg AI, Sweet CS. Comparative effects of combination drug therapy regimens commencing with either losartan potassium an angiotensin II receptor antagonist or enalapril maleate for the treatment of severe hypertension. J Hypertens 1996; 14(2): 263-70.
110. Mallion JM, Siehe JP, Lacourcière Y, Telmisartan Blood Pressure Monitoring Group. ABPM comparison of the antihypertensive profiles of the selective angiotensin II receptor antagonists telmisartan and losartan in patients with mild-to-moderate hypertension. J Hum Hypertens 1999; 13(10): 657-64.
111. Andersson OK, Neldam S. The antihypertensive effect and tolerability of candesartan cilexetil a new generation angiotensin II antagonist in comparison with losartan. Blood Pressure 1998; 7(1): 53-9.
112. Fogari R, Zoppi A, Mugellini A, Preti P, Banderali A, Pesce RM, Vanasia A. Comparative efficacy of losartan and valsartan in mild-to-moderate hypertension: Results of 24-hour ambulatory blood pressure monitoring. Curr Therap Res 1999; 60(4): 195-206.
113. Gradman A, Lewin A, Bowling BT et al. Comparative effects of candesartan cilexitil and losartan in patients with systemic hypertension. Heart Dis 1999; 1: 52-7.
114. Kassler-Taub K, Littlejohn T, Elliott W, Ruddy T, Adler E. Comparative efficacy of two angiotensin II receptor antagonists irbesartan and losartan in mild-to-moderate hypertension. Am J Hypertens 1998; 11(4): 445-53.
115. Lacourciere Y, Asmar R, for the Candesartan/Losartan study investigators. A comparison of the efficacy and duration of action of candesartan cilexetil and losartan as assessed by clinic and ambulatory blood pressure after a missed dose in truly hypertensive patients. A placebo-controlled forced titration study. Am J Hypertens 1999; 12(12): 1181-7.
116. Oparil S, Guthrie R, Lewin AJ, Marbury T, Reilly K, Triscari J, Witcher JA. An elective-titration study of the comparative effectiveness of two angiotensin II-receptor blockers irbesartan and losartan. Clin Ther 1998; 20(3): 398-409.
117. Morsing P, Adler G, Brandt-Eliasson U et al. Mechanistic differences of various AT1-receptor blockers in isolated vessels of different origin. Hypertension 1999; 33: 1406-1413.
118. Azizi M, Guyene TT, Chatellier G, Menard J: Blood pressure effects of acute intravenous renin or oral angiotensin converting enzyme inhibition in essential hypertension. J Hypertens 1994; 12(4): 419-27.
119. Fisher ND, Allan D, Kifor I, Gaboury CL, Williams GH, Moore TJ, Hollenberg NK. Responses to converting enzyme and renin inhibition. Role of angiotensin II in humans. Hypertension 1994; 23(1): 44-51.
120. Lacour C, Cazaubon C, Roccon A, Segondy D, Wagnon J, Nisato D. Effects of a renin inhibitor SR 43845 and of captopril on blood pressure and plasma active renin in conscious sodium-replete macaca. J Hypertens 1989;7(Suppl 2):S33-5.
121. Oldham AA, Arnstein MJ, Major JS, Clough DP. In vivo comparison of the renin inhibitor H77 with the angiotensin-converting enzyme inhibitor captopril. J Cardiovasc Pharmacol 1984; 6(4): 672-7.
122. Kiowski W, Beermann J, Rickenbacher P, Haemmerli R, Thomas M, Burkart F, Meinertz T. Angiotensinergic versus nonangiotensinergic hemodynamic effects of converting enzyme inhibition in patients with chronic heart failure. Assessment by acute renin and converting enzyme inhibition. Circulation 1994; 90(6): 2748-56.
123. Mento PF, Holt WF, Murphy WR, Wilkes BM. Combined renin and converting enzyme inhibition in rats. Hypertension 1989; 13(6 Pt 2): 741-8.
124. Fossa AA, Weinberg LJ, Barber RL, Rauch AL, Nocerini MR, Murphy WR, Swindell AC. Synergistic effect on reduction in blood pressure with coadministration of the renin inhibitor CP-80 794 and the angiotensin converting enzyme inhibitor captopril. J Cardiovasc Pharmacol 1992; 20(1): 75-82.
125. Allan DR, Hui KY, Coletti C, Hollenberg NK. Renin vs. angiotensin-converting enzyme inhibition in the rat: consequences for plasma and renal tissue angiotensin. J Pharmacol Exp Therap 1997 283(2): 661-5.
126. Pals DT, DeGraaf GL, Couch SJ, Brunden MN. Additive combination studies of captopril and ditekiren a renin inhibitor in non-human primates. Clin Exper Hypertens 1991; 13(3): 425-36.
127. Hollenberg NK. Pharmacologic interruption of the renin-angiotensin system and the kidney: differential responses to angiotensin-converting enzyme and renin inhibition. J Am Soc Nephrol 1999; 10(1;Suppl 11):S239-42.
128. Blumenfeld JD, Sealey JE, Mann SJ et al. Beta-adrenergic receptor blockade as a therapeutic approach for suppressing the renin-angiotensin-aldosterone system in normotensive and hypertensive subjects. Am J Hypertens 1999; 12(5): 451-9.
129. Holmer SR, Hense HW, Danser AH, Mayer B, Riegger GA, Schunkert-H. Beta adrenergic blockers lower renin in patients treated with ACE inhibitors and diuretics. Heart 1998; 80(1): 45-8.
130. Erb KA, Essig J, Breithaupt K, Belz GG. Clinical pharmacodynamic studies with cilazapril and a combination of cilazapril and propranolol. Drugs 1991; 41(Suppl 1): 11-7.
131. Van-Griensven JM, Seibert-Grafe M, Schoemaker HC, Frolich M, Cohen AF. The pharmacokinetic and pharmacodynamic interactions of ramipril with propranolol. Eur J Clin Pharmacol 1993; 45(3): 255-60.
132. Belz GG, Essig J, Kleinbloesem CH, Hoogkamer JF, Wiegand UW, Wellstein A. Interactions between cilazapril and propranolol in man; plasma drug concentrations hormone and enzyme responses haemodynamics agonist dose-effect curves and baroreceptor reflex. Br J Clin Pharmacol 1988; 26(5): 547-56.
133. Belz GG, Essig J, Erb K, Breithaupt K, Hoogkamer JF, Kneer J, Kleinbloesem CH. Pharmacokinetic and pharmacodynamic interactions between the ACE inhibitor cilazapril and beta-adrenoceptor antagonist propranolol in healthy subjects and in hypertensive patients. Br J Clin Pharm 1989; 27(Suppl): S317-22.
134. Bursztyn M, Gavras I, Gourley L, DeSilva J, Whalen J, Gavras H. Effect of combination therapy with atenolol and the angiotensin-converting enzyme inhibitor benazepril. Clinical Ther 1994; 16(3): 429-36.
135. Franz IW, Behr U, Ketelhut, R. Resting and exercise blood pressure with atenolol enalapril and a low-dose combination. J Hypertens 1987; 5(3; Suppl): S37-341.
136. Huttunen M, Lampainen E, Lilja M, Ikaheimo M, Kontro J, Makynen P, Savolainen A. Which antihypertensive to add to a beta-blocker. ACE inhibitor or diuretic? J Hum Hypertens 1992; 6(2): 121-5.
137. MacGregor GA, Markandu ND, Banks RA, Bayliss J, Roulston JE,Jones JC. Captopril in essential hypertension; contrasting effects of adding hydrochlorothiazide or propranolol. Br Med J 1982; 284(6317): 693-6.
138. MacGregor GA, Markandu ND, Smith SJ, Sagnella GA. Captopril: contrasting effects of adding hydrochlorothiazide propranolol or nifedipine. J Cardiovasc Pharmacol 1985; 7(Suppl 1):S82-287.
139. Pickering TG, Case DB, Sullivan PA, Laragh JH. Comparison of antihypertensive and hormonal effects of captopril and propranolol at rest and during exercise. Am J Cardiol 1982; 49(6): 1566-8.
140. Soininen K, Gerlin-Pilra L, Sulhkonen J et al.A study of the effects of lisinopril when used in addition to atenolol. J Hum Hypertens 1992; 6(4): 321-4.
141. Staessen J, Fagard R, Lijnen P, Verschueren LJ, Amery-A. The hypotensive effect of propranolol in captopril-treated patients does not involve the plasma renin-angiotensin-aldosterone system. Clin Sci 1981; 61(Suppl 7):S441-4.
142. Staessen J, Fagard R, Lijnen P, Verschueren LJ, Amery A. Double-blind comparison between propranolol and bendroflumethiazide in captopril-treated resistant hypertensive patients. Am Heart J 1983; 106(2): 321-8.
143. Swedish Lisinopril Study Group. Lisinopril combined with atenolol in the treatment of hypertension. J Cardiovasc Pharmacol 1991; 18(3): 457-61.
144. Wing LM, Chalmers JP, West MJ et al. Enalapril and atenolol in essential hypertension: attenuation of hypotensive effects in combination. Clin Exp Hypertens 1988; 10(1): 119-33.
145. Man-in-T-Veld AJ. Vasodilation not cardiodepression underlies the antihypertensive effect of beta-adrenoceptor antagonists. Am J Cardiol 1991; 67(10): 13B-17B.
146. Fernandez HM, Leipzig RM, Larkin RJ et al. Spironolactone in patients with heart failure. Correspondence. NEJM 2000; 342(2): 132-4.
147. McKelvie RS, Yusuf S, Pericak D et at. Comparison of Candesartan, enalapril and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. Circulation 1999; 100: 1056-64.
148. Richer C, Bruneval P, Menard J, Giudicelli JF. Additive effects of enalapril and losartan in (mREN-2)27 transgenic rats. Hypertension 1998; 31(2): 692-8.
149. Azizi M, Guyene TT, Chatellier G, Wargon M, Menard J. Additive effects of losartan and enalapril on blood pressure and plasma active renin. Hypertension 1997; 29(2): 634-40.
150. Sommers DK, Van-Wyk M, Snyman JR. Additive effects of captopril and losartan on blood pressure in mildly sodium-depleted normotensives. Clin Drug Invest 1997; 14: 321-5.
151. Bentivoglio M, Buccolieri M, Carluccio E, Mariotti M, Politano M, Tommasi S, Corea, L. The association losartanramipril in essential hypertension. Am J Hypertens 1997; 10(4 Pt 2): 131A.
152. Koval SN, Maslyaeva LV, Penkova MY, Bilovil AN, Starchenko TG. Advantages of combined use of losartan and enalapril in patients with mild arterial hypertension. Am J Hypertens 1999; 12(4): 137A.
153. Fogari R, Zoppi A, Corradi L et al. Adding losartan to lisinopril therapy in patients with hypertension: Assessment by 24-hour ambulatory blood pressure monitoring. Curr Therap Res 1999; 60(6): 326-34.
154. Zoppi A, Lazzari P, Preti P, Mugellini A, Lusardi P, Corradi L, Fogari R. Effect of lisinopril-losartan combination on insulin resistance in overweight hypertensive patients. Am J Hypertens 1998; 11(4 Pt 2): 113A.
155. Stergiou GS, Skeva II, Baibas NM, Roussias LG, Kalkana CB, Achimastos AD, Mountokalakis TD. Additive hypotensive effect of angiotensin-converting enzyme inhibition and angiotensin-receptor antagonism in essential hypertension. J Cardiovasc Pharmacol 2000: 35(6): 937-41.
156. Ruilope LM, Aldigier JC, Ponticelli C, Oddou-Stock P, Botteri F, Mann JF on behalf of the European Group for the Investigation of Valsartan in Chronic Renal Disease. Safety of the combination of valsartan and benazepril in patients with chronic renal disease. J Hypertens 2000; 18: 89-95.
157. Cooper ME, Mogensen CE for the CALM study group. Role of candesartan, lisinopril and their combination on blood pressure and albuminuria in hypertensive microalbuminuric diabetic subjects. Am J Hypertens 2000; 13(4, Pt. 2): 59A.
158. Hamroff G, Blaufarb I, Mancini D, Katz SD, Bijou R, Jondeau G, Olivari MT, Thomas S, Lejemtel TH. Angiotensin II-receptor blockade further reduces afterload safely in patients maximally treated with angiotensin-converting enzyme inhibitors for heart failure. J Cardiovasc Pharmacol 1997; 30(4): 533-6.
159. Di Pasquale P, Bucca V, Scalzo S, Paterna S. Safety tolerability and
160. Di Pasquale P, Buccaa V, Scalzoa S, Cannizzaroa S, Giubilatoa A, Paternab S. Does the addition of losartan improve the beneficial effects of ACE inhibitors in patients with anterior myocardial infarction? A pilot study. Heart 1999; 81: 606-11.
161. Riegger GA, Bouzo H, Petr P et al. Improvement in exercise tolerance and symptoms of congestive heart failure during treatment with candesartan cilexetil. Symptom, Tolerability, Response to Exercise Trial of Candesartan Cilexetil in Heart Failure (STRETCH) Investigators. Circulation 1999; 100(22): 2224-30.
162. Gradman AH, Flanagan TL, Michelson EL. Tolerability and safety of high dose angiotensin II receptor blockade with candesartan cilexetil in combination with angiotensin converting enzyme inhibition in chronic heart failure. Circulation 1999; 100(18; Suppl. I): 1783.
163. Sever PS, Holzgreve H. Long term efficacy and tolerability of candesartan cilexetil in patients with mild to moderate hypertension. J Hum Hypertens 1999; 13(Suppl 1): S69-73 1997.
164. Simko F, Simko J. Heart failure and angiotensin converting enzyme inhibition: problems and perspectives. Physiol Res 1999; 48(1): 1-8.
165. Hamroff G, Katz SD, Mancini D et al. Addition of angiotensin II receptor blockade to maximal angiotensin-converting enzyme inhibition improves exercise capacity in patients with severe congestive heart failure. Circulation 1999; 99(8): 990-2.
166. Tonkon M, Awan N, Niazi I et al. Irbesartan combined with conventional therapy including angiotensin converting enzyme inhibitors in heart failure. J Am Coll Cardiol 1998; 31(2):A188.
167. Luzier AB, DiTusa L. Underutilization of ACE inhibitors in heart failure. Pharmacotherapy 1999; 19(11): 1296-307.
168. Tanaka W, Flynn M, Sharma D et al. Plasma angiotensin II (AII) levels in heart failure patients: Effect of losartan (L) added to enalapril (E). Clin Pbannacol Therap 1998; 63(2): 177.
169. Guazzi M, Palermo P, Pontone G, Susini E, Agostoni P. Synergistic efficacy of enalapril and losartan on exercise performance and oxygen consumption at peak exercise in congestive heart failure. Am J Cardiol 1999; 84: 1038-43.
170. Spinale FG, de-Gasparo M, Whitebread S et al. Modulation of the renin-angiotensin pathway through enzyme inhibition and specific receptor blockade in pacing-induced heart failure: I. Effects on left ventricular performance and neurohormonal systems. Circulation 1997; 96(7): 2385-96.
171. Krombach RS, Clair MJ, Hendrick JW et al. Angiotensin converting enzyme inhibition ATI receptor inhibition and combination therapy with pacing induced heart failure: effects on left ventricular performance and regional blood flow patterns. Cardiovasc Res 1998; 38(3): 631-45.
172. Ogilvie RI, Zborowska SD. Captopril and angiotensin II receptor antagonist therapy in a pacing model of heart failure. Can J Cardiol 1998; 14(8): 1025-33.
173. Shen YT, Wiedmann RT, Greenland BD, Lynch JJ, Grossman W. Combined effects of angiotensin converting enzyme inhibition and angiotensin II receptor antagonism in conscious pigs with congestive heart failure. Cardiovasc Res 1998; 39(2): 413-22.
174. Spinale FG, Iannini JP, Mukherjee R, Melton DM, deGasparo M. Angiotensin ATI receptor inhibition angiotensin-converting enzyme inhibition and combination therapy with developing heart failure: cellular mechanisms of action. J Card Failure 1998; (4):325-32.
175. Spinale FG, Mukherjee R, Iannini JP et al. Modulation of the renin-angiotensin pathway through enzyme inhibition and specific receptor blockade in pacing-induced heart failure: II. Effects on myocyte contractile processes. Circulation 1997; 96(7): 2397-406.
176. Tocchi M, Rosanio S, Anzuini A, Sposi A, Mattioli D. Angiotensin II receptor blockade combined to ACE-inhibition improves left ventricular dilation and exercise ejection fraction in congestive heart failure. J Am Coll Cardiol 1998; 31(2): A188.
177. Nunez E, Hosoya K, Susie D, Frohlich ED. Enalapril and losartan reduced cardiac mass and improved coronary hemodynamics in SHR. Hypertension 1997; 29(1 Pt 2): 519-24.
178. Taylor K, Patten RD, Smith JJ, Aronovitz MJ, Wight J, Salomon RN, Konstam MA. Divergent effects of angiotensin-converting enzyme inhibition and angiotensin II-receptor antagonism on myocardial cellular proliferation and collagen deposition after myocardial infarction in rats. J Cardiovasc Pharmacol 1998; 31(5): 654-60.
179. Pfeffer MA. Enhancing cardiac protection after myocardial infarction: Rationale for newer clinical trials of angiotensin receptor blockers. Am Heart J 2000; 139(1 pt 2): 23-8.
180. Swedberg K, Pfeffer M, Granger C et al. Candesartan in heart failure-assessment of reduction in mortality and morbidity (CHARM): rationale and design. J Card Fail 1999; 5(3): 276-82.
181. Pitt B, Dickstein K, Benedict CR et al. The Randomized Angiotensin Receptor Antagonist - ACE-Inhibitor Study (RAAS) - Pilot-Study. Circulation 1996; 94(8): 12497.
182. Kasiske BL, Kalil RS, Ma JZ, Liao M, Keane WF. Effect of antihypertensive therapy on the kidney in patients with diabetes: a meta-regression analysis. Ann Intern Med 1993; 118(2): 129-38.
183. Ritz E. Nephropathy in patients with type 2 diabetes mellitus. N Engl J Med 1999; 341(15): 1127-33.
184. Dejong PE, deZeeuw D. Renoprotective therapy: titration against urinary protein excretion. Lancet 1999; 354(9176): 352-3.
185. Andersen S, Tarnow L, Rossing P, Hansen BV, Parving HH. Renoprotective effects of angiotensin II receptor blockade in type 1 diabetic patients with diabetic nephropathy. Kidney Int 2000; 57(2): 601-6.
186. Mackenzie HS, Ziai F, Omer SA, Nadim MK, Taal MW. Angiotensin receptor blockers in chronic renal disease: the promise of a bright clinical future. J Am Soc Nephrol 1999; 10(Suppl 12):S283-6.
187. Taal MW, Brenner BM. Renoprotective benefits of RAS inhibition: From ACEI to angiotensin II antagonists. Kidney Int 2000; 57: 1803-17.
188. Burdmann, EA, Andoh TF, Nast CC et al. Prevention of experimental cyclosporine-induced interstitial fibrosis by losartan and enalapril. Am J Physiol 1995; 38(4): 491-9.
189. Ots M, Mackenzie HS, Troy JL, Rennke HG, Brenner BM. Effects of combination therapy with enalapril and losartan on the rate of progression of renal injury in rats with 5/6 renal mass ablation. J Am Soc Nephrol 1998; 9(2): 224-30.
190. Weir MR, Dworkin LD. Antihypertensive drugs dietary salt and renal protection: how low should you go and with which therapy? Am J Kidney Dis 1998; 32(1): 1-22.
191. Akasu M, Urata H, Kinoshita A, Sasaguri M, Ideishi M, Arakawa K. Differences in tissue angiotensin II-forming pathways by species and organs in vitro. Hypertension 1998; 32(3): 514-20.
192. Pitt B, Segal R, Martinez FA et al. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study ELITE). Lancet 1997; 349(9054): 747-52.
193. Schmitt F, Natov S, Martinez F, Lacour B, Hannedouche TP. Renal effects of angiotensin I-receptor blockade and angiotensin convertase inhibition in man. Clin Sci 1996; 90(3): 205-13.
194. Russo D, Pisani A, Balletta M, De Nicola L, Savino FA, Andreucci M, Minutolo R. Additive antiproteinuric effect of converting enzyme inhibitor and losartan in normotensive patients with IgA nephropathy. Am J Kidney Dis 1999; 33(5): 851-6.
195. Arteaga J, Petrina E, Anda E, Calderon D, Sorbet M, Asirón M. The antiproteinuric effect of enalapril is potentiated by losartan in normotensive patients with diabetic nephropathy. Am J Hypertens 2000; 13(4; Pt. 2): 117A.
196. Geiger H. Are angiotensin II receptor blockers superior to angiotensin convening enzyme inhibitors with regard to their renoprotective effect? Nephrol Dial Transplant 1997; 12(4): 640-2.
197. Jover B, Casellas D, Mimran A, Nisato D, Cazaubon C. Renal effects of combined treatment by irbesartan and enalapril in L-NAME hypertension in rats. Naunyn Schmied Archiv Pharmacol 1998; 358(Suppl 1):3825.
198. Bakris GL, Siomos M, Bolton WK, Hebert L, Agerwall R, Catanzaro D, Janssen I. Differential Effects of Valsartan (V) and Lisinopril (L) on Potassium [K+] Homeostasis in Hypertensive Patients with Nephropathy. J Am Soc Nephrol 1999; 10(9): A0349.
199. Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor ramipril on death from cardiovascular causes myocardial infarction and stroke in high-risk patients. N Engl J Med 2000; 342(3): 145-53.